Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Huh Y, Plotka A, Wei H, Kaplan J, Raha N, Towner J, Purohit VS, Dowty ME, Wolk R, Vourvahis M, King-Ahmad A, Mathialagan S, West MA, Lazzaro S, Ryu S, Rodrigues AD. Huh Y, et al. Among authors: vourvahis m. Pharm Res. 2023 Nov;40(11):2639-2651. doi: 10.1007/s11095-023-03564-3. Epub 2023 Aug 10. Pharm Res. 2023. PMID: 37561322 Free PMC article.
Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate.
van Dyk M, Kapetas AJ, Hopkins AM, Rodrigues AD, Vourvahis M, Sorich MJ, Rowland A. van Dyk M, et al. Among authors: vourvahis m. Front Pharmacol. 2019 Sep 27;10:1120. doi: 10.3389/fphar.2019.01120. eCollection 2019. Front Pharmacol. 2019. PMID: 31611799 Free PMC article.
Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs.
Mori D, Kimoto E, Rago B, Kondo Y, King-Ahmad A, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, David Rodrigues A, Muto C, Furihata K, Sugiyama Y, Kusuhara H. Mori D, et al. Among authors: vourvahis m. Clin Pharmacol Ther. 2020 Apr;107(4):1004-1013. doi: 10.1002/cpt.1695. Epub 2020 Jan 1. Clin Pharmacol Ther. 2020. PMID: 31628668 Free PMC article. Clinical Trial.
A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker.
Luo L, Ramanathan R, Horlbogen L, Mathialagan S, Costales C, Vourvahis M, Holliman CL, Rodrigues AD. Luo L, et al. Among authors: vourvahis m. Anal Chem. 2020 Jul 21;92(14):9745-9754. doi: 10.1021/acs.analchem.0c01144. Epub 2020 Jul 2. Anal Chem. 2020. PMID: 32551505
Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein-Mediated Drug-Drug Interactions in Healthy Volunteers.
Miyake T, Kimoto E, Luo L, Mathialagan S, Horlbogen LM, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, Rodrigues AD, Muto C, Furihata K, Sugiyama Y, Kusuhara H. Miyake T, et al. Among authors: vourvahis m. Clin Pharmacol Ther. 2021 Feb;109(2):507-516. doi: 10.1002/cpt.2022. Epub 2020 Oct 9. Clin Pharmacol Ther. 2021. PMID: 32866300 Free PMC article. Clinical Trial.
56 results